Ticker: ALGN

Align Technologies

Healthcare Healthcare Medical - Devices
Price 153.62
Reco Hold Potential 54 Risk 74 Updated 2026-10-29

Forecast impact

negative
Target +33.5% target fill 74.9%
Reaction D5 -2.17% · D10 pending market trust
Impact Potential -4 · Risk +3 valid until 2026-11-20

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Align Technologies is a healthcare company specializing in digital orthodontics and dental solutions. Its core products include the Invisalign clear aligner system and iTero intraoral scanners. The company primarily generates revenue through the sale of these products and associated services, targeting both dental professionals and consumers. Align operates in the orthodontics and restorative dentistry segments, focusing on innovation and technology to enhance patient outcomes.

Investment Profile

Align Technologies presents a neutral investment profile, appealing to investors seeking growth due to its innovative product offerings and market position. However, the company's recent revenue decline and elevated risk factors suggest caution. This stock may be suitable for balanced investors looking for a mix of growth potential and stability.

Fundamental metrics (experimental) Updated: 2026-10-26
EPS (TTM) — earnings per share for the last 12 months, $
5.76
Revenue QoQ — quarter-over-quarter revenue growth
1.5%
EPS surprise
0.8%
20d volatility
1.4%
AI recommendation changes
Date Before After Reason
2026-10-23 Sell Hold Recent momentum mixed; fundamentals show slight improvement.
2026-08-24 Buy Sell Weak momentum and high risk; hold position advised.
2026-08-16 Hold Buy Strong momentum and positive earnings surprise support growth outlook.
Analyst forecasts
Date Analyst Action Target Price Then
2026-10-21 Piper Sandler Target Lowered 235 → 205 150.495
2026-10-15 Robert W. Baird Rating Downgraded — → 162 144.44
2026-10-14 Leerink Partners Target Lowered 235 → 215 143.14
News Page 1 of 1

Nothing yet